VetClick
Menu Menu
Login

VetClick

/ News
Tuesday, 13th April 2021 | 8,217 veterinary jobs online | 159 people actively seeking work | 5,085 practices registered

Veterinary Industry News

Send us your news

​Krka Launches Tuloxxin® - An Affordable Solution For Bovine Respiratory Disease (BRD)

4 months ago
415 views

Posted
30th November, 2020 09h06

Author
KRKA


Krka UK has introduced Tuloxxin®, a new product for the treatment of Bovine Respiratory Disease (BRD) triggered by Mannheimia haemolytica, Histophilus somni, Pasterella multocida and Mycoplasma bovis.  Based on proven active Tulathromycin, Tuloxxin offers additional benefits in terms of affordability and convenience in the treatment of BRD, one of the most significant diseases affecting cattle.

BRD is known to be challenging to treat for a range of reasons including its multi-factorial aetiology and identification of the cause.  This can lead to delayed treatment and the cost of appropriate therapeutics. This, in turn, can increase the need for handling, causing stress to cattle, as well as potentially increasing the overall volume of antibiotics used.  

Tuloxxin is based on the same formulation as the market leader; in cattle it is administered using a single subcutaneous injection; in sheep Tuloxxin is licensed for use in the treatment of foot rot associated with Dichelobacter nodosus and also in pigs for swine respiratory disease (SRD) administered via a single intra-muscular injection. Its fast-acting, one dose formulation supports compliance and so reduces stress to herds and flocks.   

Commenting on the launch of Tuloxxin, Charlotte Read, Key Account Manager – Farm, at Krka, said: “Without rapid treatment, confirmed cases of BRD can cause significant problems for farmers, both in terms of herd productivity and welfare. In the short-term, it slows development and is a common cause of calf mortality.  In the longer term it can also cause lasting lung damage, delays to first calving, and increased risk of culling.

“Whenever Krka launches a generic product, we aim to add some extra value to it.  Tuloxxin is a good example.  It is based on a tried and trusted active and delivers efficacy; with formulation and delivery method technology at exceptional value.  We hope its launch will support vets in their appropriate choice of antibiotic for specific cases. In so doing, they will be protecting their clients’ cattle and profitability while also playing their part in reducing antimicrobial use.”

Tuloxxin is available now from all wholesalers.

Krka UK Ltd is the UK’s fastest growing animal health company* and is a subsidiary of Slovenia-based Krka, d. d. Novo Mesto.    The company offers a range of high-quality generic pharmaceuticals and aims to offer its customers exceptional value, service and technical support.

* Kynetec Data September 2020

 

For further information:

Rebecca George, George PR

Tel: 01449 737281/07974 161108

Email: rebecca@georgepr.com


More from KRKA